BMS Archive

Plant · Scientific monograph

Bacopa monnieri

Brahmi / Water hyssop

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Cognitive Function Research, Neurological & Cognitive Research, Stress Response Research, Inflammatory Pathways

Research overview

Historical use

Bacopa monnieri (Brahmi) has been used in Ayurvedic medicine for over 3,000 years, classified as a 'medhya rasayana' — a herb that rejuvenates the intellect and memory. It was historically prescribed for epilepsy, insanity, and cognitive decline, and documented in ancient Sanskrit texts including the Charaka Samhita. Its Sanskrit name 'Brahmi' honours Brahma, the creator deity, reflecting its revered status as a brain tonic.

Modern research context

Bacopa monnieri is extensively studied as a nootropic for cognitive enhancement and neuroprotection. A 2026 double-blind, placebo-controlled RCT protocol evaluates its effects on aging and neurocognitive function including telomere length in healthy adults [1]. Network meta-analysis of randomised controlled trials identifies Bacopa monnieri among the most effective plant-derived cognitive enhancers in older adults [2]. A systematic review confirms consistent improvement in inattention, hyperactivity, and memory in ADHD populations [6]. A 2026 double-blind RCT protocol further investigates Bacopa in amnestic mild cognitive impairment and early Alzheimer's disease [8], and its mechanisms in Alzheimer's neuropathology have been reviewed in depth [5].

Adverse effects

Most commonly reported: nausea, increased intestinal motility, diarrhoea, and abdominal cramps — predominantly at the start of treatment and dose-dependent. Dry mouth and fatigue reported less frequently. GI side effects are significantly reduced when taken with food. Sedation is possible at high doses. Preclinical data demonstrate hepatorenal protective rather than toxic effects at therapeutic doses [10].

Contraindications

Avoid during pregnancy and lactation due to insufficient safety data. Caution in patients with bradycardia, thyroid conditions, or those taking thyroid medication, as cholinergic activity may slow heart rate. Avoid concurrent use with anticholinergic medications due to opposing mechanisms. Caution in patients with active GI conditions (ulcers, colitis) given its intestinal motility-enhancing effects.

Clinical and phytochemical data

Used part

Whole aerial parts (stem and leaves); standardised extracts containing 20-55% bacosides

Primary active compounds

  • Bacoside A (mixture of bacoside A3, bacopasaponin C, and jujubogenin isomers)

  • Bacoside B

  • Bacosides A1 and A2

  • Bacopasaponins C, D, E, F

  • Apigenin and luteolin (flavonoids)

  • Betulinic acid (triterpenoid)

Mechanism of action

Bacosides A and B enhance synaptic transmission by inhibiting acetylcholinesterase (AChE) and upregulating choline acetyltransferase (ChAT), increasing central cholinergic tone to support memory consolidation and learning [5]. Bacopa monnieri exerts neuroprotection through suppression of NF-κB-mediated neuroinflammation and induction of antioxidant defence genes, reducing amyloid-beta aggregation and tau hyperphosphorylation in preclinical Alzheimer's models [5]. Bacoside-mediated neurostimulation enhances synaptic plasticity through upregulation of BDNF (brain-derived neurotrophic factor) and promotes dendritic arborisation in hippocampal neurons [3]. Apoptotic anticancer activity has been demonstrated via activation of the intrinsic mitochondrial apoptosis pathway (Bax/Bcl-2 ratio shift, cytochrome c release, caspase-3 activation) in lung cancer cell lines [9]. Bacopa also modulates dopaminergic and serotonergic neurotransmission, contributing to anxiolytic and antidepressant effects [7].

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Oral bioavailability of bacosides is limited by poor aqueous solubility and first-pass hepatic metabolism; ongoing research specifically focuses on improving bioavailability through novel delivery systems [7]. Administration with food is recommended clinically to reduce GI side effects and may simultaneously improve absorption by slowing gastric transit.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Bacosides are lipid-soluble saponins capable of crossing the blood-brain barrier in animal models, consistent with the observed central neuroactive effects [3]. Tissue distribution in humans has not been formally characterised.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Bacosides undergo hepatic phase I and phase II biotransformation; the specific CYP450 isoforms involved in bacoside metabolism have not been systematically characterised in published human studies. Gut microbiota may contribute to pre-absorptive hydrolysis of saponin glycosides [7].

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Excretion routes and elimination half-life for bacosides in humans have not been established in the peer-reviewed literature retrieved for this monograph. Renal and biliary excretion of conjugated metabolites is assumed based on structural analogy with related saponins.

Safety and interactions

Drug interactions

Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.

Toxicity

Bacopa monnieri demonstrates a favourable preclinical tolerability profile at therapeutic doses. Rat studies demonstrate hepatorenal protective effects against cisplatin-induced oxidative toxicity, with Bacopa extract reducing Kidney Injury Molecule-1 (KIM-1) levels and preserving hepatic architecture [10]. GI tolerability is dose-dependent; nausea and diarrhoea are the most consistently reported adverse effects in clinical trials, resolving with dose reduction or administration with food [7]. No serious adverse events were reported in ADHD supplement trials at standard doses [6]. Long-term human data beyond 12 weeks are not available from published clinical trials; extended-use recommendations cannot be made based on current evidence.

Special precautions

Pregnancy

Insufficient human safety data available. Uterotonic effects reported in animal studies. Avoid during pregnancy.

Lactation

Bacoside excretion into breast milk has not been studied. Medicinal-dose use during lactation is not recommended due to insufficient clinical safety data.

Hepatic impairment

Hepatic biotransformation of bacosides is expected to be impaired in liver disease [7]. Preclinical data show hepatoprotective properties at therapeutic doses [10]; however, altered metabolism may lead to unpredictable plasma levels. Use with caution.

Renal impairment

Preclinical evidence demonstrates renoprotective effects at therapeutic doses [10]. No formal human pharmacokinetic or dose adjustment studies are available. Use with caution in severe renal impairment.

Sources and references

  1. [1] - Pradeep HLNR, Perera PK, Waratenne PR et al., "Effects of Bacopa monnieri herbal supplement on aging and neurocognitive functions, including neurophysiological assessments, in relation to constitution (Prakriti) in healthy adults: clinical trial protocol", Frontiers in Medicine, 2026, PMID: 41836921
  2. [2] - Feng X, Fan S, Wei F, "The effect of plant active substances on cognitive function in healthy older adults: a systematic review and network meta-analysis of randomized controlled trials", Frontiers in Pharmacology, 2025, PMID: 41640686
  3. [3] - Cipriano GL, Raffaele I, Floramo A et al., "Phytochemical and Fungal Bioactive Compounds in the Brain Health Triad: A Narrative Review on Neurostimulating, Neurotrophic, and Neuroprotective Synergy", International Journal of Molecular Sciences, 2026, PMID: 42074246
  4. [4] - Marsh A, Quelch D, Mackonochie M et al., "The efficacy of nutritional phytochemical compounds in improving cognition", International Journal of Neuropsychopharmacology, 2026, PMID: 41575193
  5. [5] - Wicinski M, Fajkiel-Madajczyk A, Wojcicki J et al., "The Role of Bacopa monnieri in Alzheimer's Disease: Mechanisms and Potential Clinical Use — A Review", Nutrients, 2025, PMID: 41305589
  6. [6] - Al Shahab S, Al Balushi R, Qambar A et al., "Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review", Nutrients, 2025, PMID: 40362791
  7. [7] - Gosciniaka A, Stasilowicz-Krzemien A, Szelag M et al., "Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability", Nutrients, 2025, PMID: 40507208
  8. [8] - Dwivedi A, Anjali A, Narzari H et al., "Efficacy of Bacopa monnieri on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial", JMIR Research Protocols, 2026, PMID: 41740144
  9. [9] - Sun JR, Zhao WM, Zhou BJ et al., "Anticancer potential of ethanolic Bacopa monnieri extract: induction of intrinsic apoptosis in A549 lung cancer cells", Journal of Physiology and Pharmacology, 2025, PMID: 41569056
  10. [10] - Sahana S, Gangachannaiah S, Maradi R et al., "Protective effects of Bacopa monnieri against cisplatin-induced hepatorenal toxicity in rats: biochemical, oxidative stress, histopathological, and Kidney Injury Molecule-1-based evidence", Veterinary World, 2026, PMID: 42046696

Additional source links

Continue browsing